company background image
FRE logo

Fresenius SE KGaA XTRA:FRE Rapport sur les actions

Dernier prix

€32.77

Capitalisation boursière

€18.5b

7D

-1.2%

1Y

18.6%

Mise à jour

19 Nov, 2024

Données

Finances de l'entreprise +

Fresenius SE & Co. KGaA

XTRA:FRE Rapport sur les actions

Capitalisation boursière : €18.5b

FRE Aperçu des actions

Fresenius SE & Co. KGaA, une entreprise de soins de santé, fournit des produits et des services pour les patients souffrant de maladies chroniques. Plus de détails

FRE analyse fondamentale
Score flocon de neige
Évaluation5/6
Croissance future3/6
Performances passées0/6
Santé financière4/6
Dividendes0/6

Récompenses

Se négocie à 63.4% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 38.96% par an

Les analystes s'accordent à dire que le prix des actions augmentera de 22.2%

Analyse des risques

A un niveau d'endettement élevé


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Biopharma Innovations And Critical Growth Initiatives Propel Earnings And Margin Expansion

Key Takeaways Strategic initiatives focused on productivity and organic growth are expected to enhance operational efficiency and drive margin expansion. Successful biosimilar launches and market access efforts support sustained revenue growth and improved financial flexibility.
View narrative
€39.99
FV
18.1% undervalued intrinsic discount
3.03%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
13 days ago author updated this narrative
TO
Tokyo
Community Contributor

First comes the pain, then the money.

My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).
View narrative
€74.00
FV
55.7% undervalued intrinsic discount
24.16%
Revenue growth p.a.
3users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
4 months ago author updated this narrative

Fresenius SE & Co. KGaA Concurrents

Fresenius Medical Care

XTRA:FME

€12.2b

SYNLAB

HMSE:SYAB

€2.5b

Siemens Healthineers

XTRA:SHL

€55.1b

Labcorp Holdings

NYSE:LH

US$19.8b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Fresenius SE KGaA
Historique des cours de bourse
Prix actuel de l'action€32.77
Plus haut sur 52 semaines€36.24
Plus bas sur 52 semaines€24.32
Bêta1.04
1Variation sur 1 mois-2.03%
Variation sur 3 mois1.64%
Variation sur 1 an18.65%
3Variation sur 3 ans-7.70%
Variation sur 5 ans-34.04%
Évolution depuis l'introduction en bourse2,802.59%

Nouvelles et mises à jour récentes

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Recent updates

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jul 15
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

Jun 12
Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28
At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02
With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29
Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13
Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06
Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19
A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03
Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Nov 28
Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10
Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27
Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25
Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01
At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18
Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13
Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23
Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08
Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03
The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28
These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23
Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01
The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07
Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20
Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02
Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28
Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17
At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02
Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27
Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24
Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Rendement pour les actionnaires

FREDE HealthcareDE Marché
7D-1.2%0.8%-0.2%
1Y18.6%17.2%7.8%

Rendement vs Industrie: FRE correspondait au secteur German Healthcare qui a rapporté 17.2 % au cours de l'année écoulée.

Rendement vs marché: FRE a dépassé le marché German qui a rapporté 7.8 % au cours de l'année écoulée.

Volatilité des prix

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement2.5%
Healthcare Industry Average Movement4.0%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.1%
10% least volatile stocks in DE Market2.4%

Cours de l'action stable: FRE n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de FRE ( 3% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
1912177,091Michael Senwww.fresenius.com

Fresenius SE & Co. KGaA, une société de soins de santé, fournit des produits et des services pour les patients souffrant de maladies chroniques. Elle opère à travers quatre segments : Fresenius Medical Care, Fresenius Kabi, Fresenius Helios et Fresenius Vamed. Le segment Fresenius Medical Care offre des produits et des services aux patients souffrant d'insuffisance rénale chronique.

Fresenius SE & Co. KGaA Résumé des fondamentaux

Comment les bénéfices et les revenus de Fresenius SE KGaA se comparent-ils à sa capitalisation boursière ?
FRE statistiques fondamentales
Capitalisation boursière€18.46b
Bénéfices(TTM)-€479.00m
Recettes(TTM)€22.81b

0.8x

Ratio P/S

-38.5x

Ratio P/E

Le site FRE est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
FRE compte de résultat (TTM)
Recettes€22.81b
Coût des recettes€17.48b
Marge brute€5.33b
Autres dépenses€5.81b
Les revenus-€479.00m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-0.85
Marge brute23.37%
Marge bénéficiaire nette-2.10%
Ratio dettes/capitaux propres60.9%

Quelles ont été les performances à long terme de FRE?

Voir les performances historiques et les comparaisons